Sintilimab
- Generic Name
- Sintilimab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 2072873-06-2
- Unique Ingredient Identifier
- 8FU7FQ8UPK
- Associated Conditions
- -
- Associated Therapies
- -
Systemic Chemotherapy, Apatinib Plus Sintilimab for Metastasis ICC
- First Posted Date
- 2020-12-23
- Last Posted Date
- 2021-02-04
- Lead Sponsor
- Sun Yat-sen University
- Registration Number
- NCT04682249
- Locations
- 🇨🇳
Cancer Center Sun Yat-sen University, Guangzhou, Guangdong, China
Sintilimab Plus Bevacizumab as Adjuvant Therapy in HCC Patients at High Risk of Recurrence After Curative Resection
- Conditions
- Interventions
- First Posted Date
- 2020-12-23
- Last Posted Date
- 2020-12-23
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 246
- Registration Number
- NCT04682210
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
A Study of Sintilimab Plus Ramucirumab as First-line Treatment for G/EGJ Adenocarcinoma (ORIENT-106)
- Conditions
- Interventions
- First Posted Date
- 2020-12-19
- Last Posted Date
- 2023-03-02
- Lead Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Target Recruit Count
- 36
- Registration Number
- NCT04675983
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, China
Sintilimab Plus R-GemOx as Second-line Salvage Therapy in Patients With R/R DLBCL
- Conditions
- Interventions
- First Posted Date
- 2020-12-09
- Last Posted Date
- 2020-12-09
- Lead Sponsor
- Qian Wenbin
- Target Recruit Count
- 51
- Registration Number
- NCT04659434
- Locations
- 🇨🇳
2nd Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China
Sintilimab Plus Hypofractionated Radiotherapy for MSI-H/dMMR Rectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-11-19
- Last Posted Date
- 2024-08-06
- Lead Sponsor
- West China Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT04636008
- Locations
- 🇨🇳
West China Hospital of Sichuan University, Chengdu, Sichuan, China
Lenvatinib Combined Anti-PD1 Antibody for the Advanced Hepatocellular Carcinoma
- Conditions
- First Posted Date
- 2020-11-13
- Last Posted Date
- 2024-03-06
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 600
- Registration Number
- NCT04627012
- Locations
- 🇨🇳
Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China
HAIC Combined With Lenvatinib and Sintilimab for Hepatocellular Carcinoma With PVTT
- Conditions
- Interventions
- First Posted Date
- 2020-11-05
- Last Posted Date
- 2024-03-06
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 30
- Registration Number
- NCT04618367
- Locations
- 🇨🇳
Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China
A Phase II Study of Anti-PD-1 Antibody, Sintilimab, as Second-line Therapy for Biomarker-selected Advanced or Metastatic NSCLC
- First Posted Date
- 2020-11-03
- Last Posted Date
- 2020-11-03
- Lead Sponsor
- China Medical University, China
- Target Recruit Count
- 33
- Registration Number
- NCT04612673
- Locations
- 🇨🇳
The First Affiliated Hospital of China Medical University, Shenyang, Liaoning, China
Sintilimab Injection Combined With Concurrent CCRT in Locally Advanced Esophageal Squamous Cell Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2020-10-26
- Last Posted Date
- 2020-10-26
- Lead Sponsor
- Sichuan Cancer Hospital and Research Institute
- Target Recruit Count
- 53
- Registration Number
- NCT04602013
- Locations
- 🇨🇳
Sichuan Cancer Hospital & Institute, Chengdu, Sichuan, China
A Phase II Clinical Study to Assess the Efficacy and Safety of IBI310 or Placebo Combined With Sintilimab for Advanced Cervical Cancer Subjects Who Have Failed or Cannot Tolerate First-line or Above Platinum-based Chemotherapy
- Conditions
- Interventions
- First Posted Date
- 2020-10-19
- Last Posted Date
- 2023-12-18
- Lead Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Target Recruit Count
- 205
- Registration Number
- NCT04590599
- Locations
- 🇨🇳
Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital）, Zhenjiang, China
🇨🇳Innovent Biologics, Inc., Suzhou, Jiangsu, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.